AN2 Therapeutics finds itself at a critical juncture following the setback with epetraborole. While challenges remain, the company's expertise in boron-chemistry and diversified pipeline provide ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived fro ...

AN2 Therapeutics is rethinking its business in response to lackluster midphase data, vowing to lay off half its employees and stop a phase 3 study as part of a pivot to early-stage projects. The ...

Poland's air force on 14 December withdrew the last of its Antonov An-2 utility aircraft from use, almost 60 years after fielding the biplane type.

Roy Buchanan has given his Buy rating due to a combination of factors that highlight the promising potential of AN2 Therapeutics’ oral drug, epetraborole, in treating mycobacterium avium complex ...

License enables advancement of AN2-502998 (formerly known as AN15368), a boron-based small molecule therapeutic under development for the treatment of Chagas disease IND-enabling preclinical ...

Given this risk, we thought we'd take a look at whether AN2 Therapeutics (NASDAQ:ANTX) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...

AN2 Therapeutics has found public investors willing to bet on biotech, enabling it to upsize its IPO and reel in $69 million for a pivotal trial of an antibiotic it picked up from Pfizer’s ...

AN2 Therapeutics said on Monday it will pause further enrollment in a late-stage study testing its experimental lead drug due to potentially lower-than-expected efficacy, sending shares down 65% ...

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that ...